Ann: Elanco Option Update, page-103

I think that's possible. I noticed too that he seemed to emphasize that they now know the value of having 25% of subjects with tumor regression vs 75%, and that they are confident that with optimized dosing, they can pick up those numbers. Frustrating, but it looks like a better deal could be struck in future. Roger seems intent on maintaining relationship with Elanco. Lets hope Covid-19 trials and human cancer trials can keep them busy in the mean time. After all, that's where the big money is. I'm at least confident that they're pretty well cashed up- needing to come to the market for a raise now would have been worse.